Intergenerational mobility of housework time in the United Kingdom

This paper analyzes the relationship between parents’ time devoted to housework and the time devoted to housework by their children. Using data from the Multinational Time Use Study for the UK, we find positive intergenerational correlations in housework for both parents, indicating that the more time parents devote to housework, the more time their children will devote to housework. Using data from the British Household Panel Survey, we find that a higher father–mother housework ratio is positively related to a higher child–mother housework ratio, even after allowing for individual fixed-effects. In order to address the potential exacerbation of errors-in-variables arising from the fixed-effects specification, we instrument the father–mother ratio of housework using father’s and mother’s lagged weekly working hours. The Instrumental-Variable estimates fully support the fixed-effects estimates, and suggest that the latter should be regarded as a lower bound. We also present evidence of the link between housework during adolescence and duringadulthood, which may indicate that housework time during adulthood depends on the housework time during childhood, which may also be affected by parents’ housework time. Our results contribute to the field of the intergenerational mobility of behaviors

Mineralisation of crop residues on the soil surface or incorporated in the soil under controlled conditions

In the present work, we compare the effect of mature crop residues mixed into a ferralitic soil or placed as a single layer on soil surface on the mineralisation of C and N over 55 days. As residues, we used dry stems of rice, soybean, sorghum, brachiaria and wheat. There were no significant effects of residue placement on C mineralisation kinetics. Decomposition of the residues on the soil surface slightly increased net N mineralisation for residues having the smallest C/N ratio

Chemically-Induced Cancers Do Not Originate from Bone Marrow-Derived Cells

BACKGROUND: The identification and characterization of cancer stem cells (CSCs) is imperative to understanding the mechanism of cancer pathogenesis. Growing evidence suggests that CSCs play critical roles in the development and progression of cancer. However, controversy exists as to whether CSCs arise from bone marrow-derived cells (BMDCs). METHODOLOGY AND PRINCIPAL FINDINGS: In the present study, n-nitrosodiethylamine (DEN) was used to induce tumor formation in female mice that received bone marrow from male mice. Tumor formation was induced in 20/26 mice, including 12 liver tumors, 6 lung tumors, 1 bladder tumor and 1 nasopharyngeal tumor. Through comparison of fluorescence in situ hybridization (FISH) results in corresponding areas from serial tumor sections stained with HandE, we determined that BMDCs were recruited to both tumor tissue and normal surrounding tissue at a very low frequency (0.2-1% in tumors and 0-0.3% in normal tissues). However, approximately 3-70% of cells in the tissues surrounding the tumor were BMDCs, and the percentage of BMDCs was highly associated with the inflammatory status of the tissue. In the present study, no evidence was found to support the existence of fusion cells formed form BMDCs and tissue-specific stem cells. CONCLUSIONS: In summary, our data suggest that although BMDCs may contribute to tumor progression, they are unlike to contribute to tumor initiation.published_or_final_versio

Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial

BackgroundPatients with acute myeloid leukemia (AML) who have tumor protein p53 (TP53) mutations or a complex karyotype have a poor prognosis, and hypomethylating agents are often used. The authors evaluated the efficacy of entospletinib, an oral inhibitor of spleen tyrosine kinase, combined with decitabine in this patient population.MethodsThis was a multicenter, open-label, phase 2 substudy of the Beat AML Master Trial (ClinicalTrials.gov identifier NCT03013998) using a Simon two-stage design. Eligible patients aged 60 years or older who had newly diagnosed AML with mutations in TP53 with or without a complex karyotype (cohort A; n = 45) or had a complex karyotype without TP53 mutation (cohort B; n = 13) received entospletinib 400 mg twice daily with decitabine 20 mg/m2 on days 1-10 every 28 days for up to three induction cycles, followed by up to 11 consolidation cycles, in which decitabine was reduced to days 1-5. Entospletinib maintenance was given for up to 2 years. The primary end point was complete remission (CR) and CR with hematologic improvement by up to six cycles of therapy.ResultsThe composite CR rates for cohorts A and B were 13.3% (95% confidence interval, 5.1%-26.8%) and 30.8% (95% confidence interval, 9.1%-61.4%), respectively. The median duration of response was 7.6 and 8.2 months, respectively, and the median overall survival was 6.5 and 11.5 months, respectively. The study was stopped because the futility boundary was crossed in both cohorts.ConclusionsThe combination of entospletinib and decitabine demonstrated activity and was acceptably tolerated in this patient population; however, the CR rates were low, and overall survival was short. Novel treatment strategies for older patients with TP53 mutations and complex karyotype remain an urgent need

An overview of tissue engineering approaches for management of spinal cord injuries

Severe spinal cord injury (SCI) leads to devastating neurological deficits and disabilities, which necessitates spending a great deal of health budget for psychological and healthcare problems of these patients and their relatives. This justifies the cost of research into the new modalities for treatment of spinal cord injuries, even in developing countries. Apart from surgical management and nerve grafting, several other approaches have been adopted for management of this condition including pharmacologic and gene therapy, cell therapy, and use of different cell-free or cell-seeded bioscaffolds. In current paper, the recent developments for therapeutic delivery of stem and non-stem cells to the site of injury, and application of cell-free and cell-seeded natural and synthetic scaffolds have been reviewed